stock PURCHASE AGREEMENTStock Purchase Agreement • May 4th, 2017 • Agenus Inc • Biological products, (no disgnostic substances)
This Stock Purchase Agreement (this “Agreement”) is dated as of February 14, 2017, between Agenus Inc., a Delaware corporation (the “Company”), and Incyte Corporation, a Delaware corporation (the “Purchaser”).
April 1, 2017Separation Agreement • May 4th, 2017 • Agenus Inc • Biological products, (no disgnostic substances) • Massachusetts
As we have discussed, you have voluntarily retired from your employment with Agenus Inc. (the “Company”), effective as of April 1, 2017 (the “Separation Date”). The purpose of this letter agreement (“Agreement”) is to confirm the understanding between you and the Company concerning your separation benefits, as follows:
FIRST AMENDMENT TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • May 4th, 2017 • Agenus Inc • Biological products, (no disgnostic substances)
For clarity, no other milestones set forth in the Original Agreement shall apply with respect to the OX-40 Project or the GITR Project, and the milestones set forth in (F) through (H) above are payable only once across all Royalty-Bearing Products, based on aggregate sales of LAG-3 Products, TIM-3 Products, [********] Products, GITR Products, and OX-40 Products.
CONSULTING AGREEMENTConsulting Agreement • May 4th, 2017 • Agenus Inc • Biological products, (no disgnostic substances) • New York
This Consulting Agreement (this “Agreement”), effective as of April 1, 2017 (the “Effective Date”) is made between Agenus Inc., a Delaware corporation, having an address at 149 Fifth Avenue, Suite 500, New York, NY 10010 (“Agenus”), and Dr. Robert Stein, an individual currently residing at 7 Peter Cooper Rd., Apt 10-B, New York, NY 10010 (the “Consultant”) (each a “Party” and collectively the “Parties”).
